The HLCS technology is dead. nobody is going to purchase a $800,000 single molecule machine when the next generation of sequencing is obviously going digital.
They should have sold last year. Now they have an antiquated technology that is still riddled with bugs.
Still, the tool from Ion Torrent is likely to be useful in many ways, Smith says. It might be used by researchers who want a quick, easy genomic readout on other organisms like bacteria or viruses, or certain regions of DNA that are of interest in a specific human tissue, Smith says. Because of the low cost, speed, and simplicity for the user, it could lend itself over time to diagnostic applications, Smith says. And importantly, the low purchase cost of $50,000, compared to $500,000 for other machines, could enable Ion Torrent to “democratize” sequencing by selling its instrument to a broader pool of biologists than just the small group of people who run hard-core sequencing centers. That could unleash the creative juices of many smart scientists who don’t really have easy access to sequencers but could do cool things if they did, Smith says. The machine also is likely to increase its throughput over time, as semiconductor speed and power increases.
The news from Ion Torrent is really just the latest step in the world of DNA sequencing, which has been on a breakneck pace to make sequencing better, faster, and cheaper. Illumina announced in January that it is now possible on its machines to sequence entire human genomes for as little as $10,000. Mountain View, CA-based Complete Genomics says it can do the same job for $5,000, largely because it has a different model in which it doesn’t sell machines, but rather it asks researchers send their samples to a centralized company lab. We’ve also written about other companies that are developing machines that aspire to push the leading edge of speed and cost, including U.K.-based Oxford Nanopore Technologies and Providence, RI-based NABsys.
It all sounds great. But like anything new, Ion Torrent will have to prove that it can do what it says it can do, Smith says.
Hooey. It's not installed anywhere yet, they're doing 2 "grant placements" this year, no market share, no track record.
Accuracy for a 34-kilobase adenovirus genome (small chain): 99.99999%. Accuracy for a 4.6-megabase E-coli read: 99.9%. That is four orders of magnitude LESS accurate for a longer read.
Still appears to require amplification. Don't see any mention of sample sizes.
No timeline for commercial release.
Above info from here:
Don't forget someone gobbled up those shares today. They must really be misguided.
Some HLCS news would, of course, be very welcome at this point. But I have a firm grip on my coconuts!